Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: The Roman experience

Carlo Pozzilli, L. Prosperini, E. Sbardella, L. De Giglio, E. Onesti, V. Tomassini

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Safety, tolerability and efficacy profiles of interferon beta (IFNβ) therapy in relapsing multiple sclerosis (MS) has been widely verified both in trial settings and in daily clinical practice. However, for a variable percentage of treated patients, it remains only partially effective. In this study, we reported the post-marketing experience of the efficacy of IFNβ therapy for a large cohort of MS patients regularly attending the MS Outpatient Clinic of "La Sapienza University" in Rome. In this cohort we also sought clinical and paraclinical variables responsible for the clinical course of MS during IFNβ therapy. Patients that received treatment with one of the IFNβ formulations for at least 1 year were included. Clinical outcomes (i. e., relapses and disability score) were monitored throughout the entire study period. Magnetic resonance imaging (MRI) scans were performed twice for each subject: at baseline and after 1 year of therapy. The occurrence of more than one relapse during the study period or a sustained disability progression in the Expanded Disability Status Scale (EDSS) score were considered as criteria for the definition of suboptimal clinical response to IFNβ therapy. During IFNβ therapy (number of patients 242, mean length of treatment 4.3±2.3 years) a reduction in the annualised relapse rate of 59% (p

Original languageEnglish
JournalNeurological Sciences
Volume26
Issue numberSUPPL. 4
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Interferon-beta
Marketing
Multiple Sclerosis
Therapeutics
Recurrence
Surveys and Questionnaires
Ambulatory Care Facilities
Magnetic Resonance Imaging
Safety

Keywords

  • Disability progression
  • Interferon beta
  • MRI
  • Multiple sclerosis
  • Predictors of response
  • Relapse rate

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis : The Roman experience. / Pozzilli, Carlo; Prosperini, L.; Sbardella, E.; De Giglio, L.; Onesti, E.; Tomassini, V.

In: Neurological Sciences, Vol. 26, No. SUPPL. 4, 12.2005.

Research output: Contribution to journalArticle

Pozzilli, Carlo ; Prosperini, L. ; Sbardella, E. ; De Giglio, L. ; Onesti, E. ; Tomassini, V. / Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis : The Roman experience. In: Neurological Sciences. 2005 ; Vol. 26, No. SUPPL. 4.
@article{768dce1c9a274267829a0d4acdf86f46,
title = "Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: The Roman experience",
abstract = "Safety, tolerability and efficacy profiles of interferon beta (IFNβ) therapy in relapsing multiple sclerosis (MS) has been widely verified both in trial settings and in daily clinical practice. However, for a variable percentage of treated patients, it remains only partially effective. In this study, we reported the post-marketing experience of the efficacy of IFNβ therapy for a large cohort of MS patients regularly attending the MS Outpatient Clinic of {"}La Sapienza University{"} in Rome. In this cohort we also sought clinical and paraclinical variables responsible for the clinical course of MS during IFNβ therapy. Patients that received treatment with one of the IFNβ formulations for at least 1 year were included. Clinical outcomes (i. e., relapses and disability score) were monitored throughout the entire study period. Magnetic resonance imaging (MRI) scans were performed twice for each subject: at baseline and after 1 year of therapy. The occurrence of more than one relapse during the study period or a sustained disability progression in the Expanded Disability Status Scale (EDSS) score were considered as criteria for the definition of suboptimal clinical response to IFNβ therapy. During IFNβ therapy (number of patients 242, mean length of treatment 4.3±2.3 years) a reduction in the annualised relapse rate of 59{\%} (p",
keywords = "Disability progression, Interferon beta, MRI, Multiple sclerosis, Predictors of response, Relapse rate",
author = "Carlo Pozzilli and L. Prosperini and E. Sbardella and {De Giglio}, L. and E. Onesti and V. Tomassini",
year = "2005",
month = "12",
doi = "10.1007/s10072-005-0510-x",
language = "English",
volume = "26",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis

T2 - The Roman experience

AU - Pozzilli, Carlo

AU - Prosperini, L.

AU - Sbardella, E.

AU - De Giglio, L.

AU - Onesti, E.

AU - Tomassini, V.

PY - 2005/12

Y1 - 2005/12

N2 - Safety, tolerability and efficacy profiles of interferon beta (IFNβ) therapy in relapsing multiple sclerosis (MS) has been widely verified both in trial settings and in daily clinical practice. However, for a variable percentage of treated patients, it remains only partially effective. In this study, we reported the post-marketing experience of the efficacy of IFNβ therapy for a large cohort of MS patients regularly attending the MS Outpatient Clinic of "La Sapienza University" in Rome. In this cohort we also sought clinical and paraclinical variables responsible for the clinical course of MS during IFNβ therapy. Patients that received treatment with one of the IFNβ formulations for at least 1 year were included. Clinical outcomes (i. e., relapses and disability score) were monitored throughout the entire study period. Magnetic resonance imaging (MRI) scans were performed twice for each subject: at baseline and after 1 year of therapy. The occurrence of more than one relapse during the study period or a sustained disability progression in the Expanded Disability Status Scale (EDSS) score were considered as criteria for the definition of suboptimal clinical response to IFNβ therapy. During IFNβ therapy (number of patients 242, mean length of treatment 4.3±2.3 years) a reduction in the annualised relapse rate of 59% (p

AB - Safety, tolerability and efficacy profiles of interferon beta (IFNβ) therapy in relapsing multiple sclerosis (MS) has been widely verified both in trial settings and in daily clinical practice. However, for a variable percentage of treated patients, it remains only partially effective. In this study, we reported the post-marketing experience of the efficacy of IFNβ therapy for a large cohort of MS patients regularly attending the MS Outpatient Clinic of "La Sapienza University" in Rome. In this cohort we also sought clinical and paraclinical variables responsible for the clinical course of MS during IFNβ therapy. Patients that received treatment with one of the IFNβ formulations for at least 1 year were included. Clinical outcomes (i. e., relapses and disability score) were monitored throughout the entire study period. Magnetic resonance imaging (MRI) scans were performed twice for each subject: at baseline and after 1 year of therapy. The occurrence of more than one relapse during the study period or a sustained disability progression in the Expanded Disability Status Scale (EDSS) score were considered as criteria for the definition of suboptimal clinical response to IFNβ therapy. During IFNβ therapy (number of patients 242, mean length of treatment 4.3±2.3 years) a reduction in the annualised relapse rate of 59% (p

KW - Disability progression

KW - Interferon beta

KW - MRI

KW - Multiple sclerosis

KW - Predictors of response

KW - Relapse rate

UR - http://www.scopus.com/inward/record.url?scp=30644462726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30644462726&partnerID=8YFLogxK

U2 - 10.1007/s10072-005-0510-x

DO - 10.1007/s10072-005-0510-x

M3 - Article

C2 - 16388353

AN - SCOPUS:30644462726

VL - 26

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - SUPPL. 4

ER -